Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 85, Issue 5, 2007, Pages 408-414

  Zver, Samo ^a   Zadnik, Vesna ^b   Bunc, Matjaz ^a   Rogel, Polona ^c   Cernelc, Peter ^a   Kozelj, Mirta ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c Institute of Physiology   (Slovenia)

Author keywords

Cardiac toxicity; Cyclophosphamide; HSCT; Multiple myeloma

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENDOTHELIN 1; EPIRUBICIN; MESNA; TROPONIN I; VINCRISTINE; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HUMAN; MALE; MITRAL VALVE REGURGITATION; MULTIPLE MYELOMA; AUTOTRANSPLANTATION; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIASTOLE; ECHOGRAPHY; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; DIASTOLE; ECHOCARDIOGRAPHY; ENDOTHELIN-1; FEMALE; GRAFT REJECTION; HEART FAILURE, CONGESTIVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NATRIURETIC PEPTIDE, BRAIN; TRANSPLANTATION, AUTOLOGOUS; TROPONIN I;

EID: 34548441664     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0620     Document Type: Article

References (40)

1. Attal M, Harousseau J-L, Stoppa A-M, et al, for The Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
2. Child JA, Gareth JM, Davies FE, et al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
3. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
4. Attal M, Harousseau J-L, Facon T, et al, for the InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
5. Kupari M, Volin L, Soukas A, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance. J Intern Med. 1990;227:259-266.
6. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1998;6:1562-1568.
7. Auner HW, Tinchon C, Brezinschek RI, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol. 2002;69:1-6.
8. Mori T, Yanagi N, Moruyama T, et al. Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. Jpn Heart J. 2002;43:249-261.
9. Buja LM, Ferrans VJ, Graw RG Jr. Cardiac pathologic findings in patients treated with bone marrow transplantation. Human Pathol. 1976;7:17-45.
10. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758-763.
11. Antman EM. Decision making with cardiac troponin tests. N Engl J Med. 2002;346:2079-2082.
12. Mark DB, Felker M. B-type natriuretic peptide: a biomarker for all seasons. N Engl J Med. 2004;350:718-720.
13. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
14. Nousianen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251:228-234.
15. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail. 2004;6:295-300.
16. Levin ER. Endothelins. N Engl J Med. 1995;333:356-361.
17. Nakamura S, Naruse M, Naruse K, Demura H, Uemura H. Immunocytochemical localization of endothelin in cultured bovine endothelial cells. Histochemistry. 1990;94:475-477.
18. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation. 1994;89:1580-1586.
19. Giannuzzi P, Temporelli PL, Bossimi E, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol. 1996;28:383-390.
20. Benvenuto GM, Ometto R, Fontanelli A, et al. Chemotherapy-related cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J. 2003;10:655-667.
21. Suzuki J, Yanagisawa A, Shigeyama T, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology. 1999;50:37-45.
22. 2) cyclophosphamide. Bone Marrow Transplant. 2001;28:277-282.
23. Venge P, Johnston N, Lagerquist B, Wallentin L, Lindahl B, and the FRISC-II Study Group. Clinical and analytical performance of the Liaison cardiac troponin I assay in unstable coronary artery disease and the impact of age on the definition of reference limits: a FRISC-II Substudy. Clin Chem. 2003;49:880-886.
24. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond). 1998;95:519-529.
25. Okishima N, Hajiwara Y, Seito T, Yano M, Kido H. Specific sandwich-type enzyme immunoassays for smooth muscle constricting novel 31-amino acid endothelins. Biochem Biophys Res Commun. 1999;256:1-5.
26. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7-11.
27. Lewis JF, Kuo LC, Nelson JG, Limacher MC, Quinones MA. Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation. 1984;70:425-431.
28. Appleton CP, Firstenberg MS, Garcia MJ, Thomas JD. The echo-Doppler evaluation of left ventricular diastolic function: a current prospective. Cardiol Clin. 2000;18:513-546.
29. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114-1118.
30. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf. 2002;25:301-311.
31. Morjana NA. Degradation of human cardiac troponin I after myocardial infarction. Biotechnol Appl Biochem. 1998;28:105-111.
32. Klootwijk P, Hamm C. Acute coronary syndromes: diagnosis. Lancet. 1999;353(suppl 2):SII10-SII15.
33. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-2754.
34. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med. 1999;134:437-444.
35. Cowburn PJ, Cleland JGF. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J. 2001;22:1772-1784.
36. Luescher TF, Barton M. Endothelins and endothelin receptors antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
37. Benvenuto GM, La Vecchia L, Morandi P, Ruffini PA, Mezzena G. Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors [in Italian]. Ital Heart J Suppl. 2000;1:1457-1463.
38. Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E. Cardiotoxicity of epirubicin and doxorubicin: a double blind randomised study. Eur J Haematol. 1991;46:301-305.
39. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263-302.
40. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16:3502-3508.